FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136165535> ?p ?o ?g. }

• W3136165535 abstract "Abstract Background Non-small-cell lung cancer (NSCLC) is usually diagnosed at an advanced stage, and chemotherapy is the main treatment for this disease. Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China. KLTi combined with chemotherapy could improve the short-term efficacy, quality of life, and performance status for NSCLC compared with chemotherapy alone. This trial aims to assess the long-term efficacy and safety of KLTi in combination with chemotherapy for the treatment of advanced NSCLC. Methods This will be an investigator-initiated multicenter open-label randomized controlled trial. We will randomly assign 334 eligible participants with stage IIIA-IV NSCLC to the treatment or control groups in a 1:1 ratio. Patients in both groups will be administered 4–6 cycles of first-line platinum-based double chemotherapy regimens. Patients with complete response, partial response, or stable disease after 4–6 cycles will receive non-platinum single-agent chemotherapy. Patients in the treatment group are to receive intravenous KLTi 200 ml per day continuously for 14 days, commencing on the first day of chemotherapy. The treatment will be discontinued at the time of disease progression or until unacceptable toxicity is noted. The follow-up will be conducted every 2 months until death, loss of follow-up, or 12 months from randomized enrollment. The primary outcome will be progression-free survival (PFS). The secondary outcomes will be the objective response rate, 1-year survival rate, quality of life, living ability, and blood lipids. The safety outcome will be the rate of adverse events. Discussion This study will be the first randomized controlled trial in which PFS is used as the primary outcome to test whether KLTi combined with first-line chemotherapy has superior efficacy and reduced toxicity compared to chemotherapy alone in advanced NSCLC. This will also be the first clinical study to observe the effects of KLTi on blood lipids. Trial registration ClinicalTrials.gov NCT03986528. Prospectively registered on 30 May 2019." @default.
• W3136165535 created "2021-03-29" @default.
• W3136165535 creator A5003649889 @default.
• W3136165535 creator A5006829574 @default.
• W3136165535 creator A5028097742 @default.
• W3136165535 creator A5036487477 @default.
• W3136165535 creator A5041492237 @default.
• W3136165535 creator A5042973046 @default.
• W3136165535 creator A5053399096 @default.
• W3136165535 creator A5069537747 @default.
• W3136165535 creator A5081143070 @default.
• W3136165535 date "2021-03-17" @default.
• W3136165535 modified "2023-09-24" @default.
• W3136165535 title "Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial" @default.
• W3136165535 cites W1487089774 @default.
• W3136165535 cites W1988314473 @default.
• W3136165535 cites W1992417682 @default.
• W3136165535 cites W1993382872 @default.
• W3136165535 cites W1994769053 @default.
• W3136165535 cites W2009664217 @default.
• W3136165535 cites W2019607817 @default.
• W3136165535 cites W2024586113 @default.
• W3136165535 cites W2028889234 @default.
• W3136165535 cites W2031212516 @default.
• W3136165535 cites W2041025544 @default.
• W3136165535 cites W2050249255 @default.
• W3136165535 cites W2076668534 @default.
• W3136165535 cites W2087381758 @default.
• W3136165535 cites W2112621029 @default.
• W3136165535 cites W2114371152 @default.
• W3136165535 cites W2121915336 @default.
• W3136165535 cites W2129618555 @default.
• W3136165535 cites W2131785306 @default.
• W3136165535 cites W2132157071 @default.
• W3136165535 cites W2134964659 @default.
• W3136165535 cites W2135077538 @default.
• W3136165535 cites W2140075859 @default.
• W3136165535 cites W2153169173 @default.
• W3136165535 cites W2167571044 @default.
• W3136165535 cites W2469644670 @default.
• W3136165535 cites W2501050148 @default.
• W3136165535 cites W2518488558 @default.
• W3136165535 cites W2560062861 @default.
• W3136165535 cites W2590359520 @default.
• W3136165535 cites W2734670400 @default.
• W3136165535 cites W2762423488 @default.
• W3136165535 cites W2888031957 @default.
• W3136165535 cites W2889646458 @default.
• W3136165535 cites W2892640821 @default.
• W3136165535 cites W2951071083 @default.
• W3136165535 cites W2994703468 @default.
• W3136165535 cites W3003494347 @default.
• W3136165535 cites W3037014259 @default.
• W3136165535 cites W3122247511 @default.
• W3136165535 cites W4210992155 @default.
• W3136165535 cites W613093006 @default.
• W3136165535 doi "https://doi.org/10.1186/s13063-021-05169-w" @default.
• W3136165535 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7966914" @default.
• W3136165535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33731199" @default.
• W3136165535 hasPublicationYear "2021" @default.
• W3136165535 type Work @default.
• W3136165535 sameAs 3136165535 @default.
• W3136165535 citedByCount "1" @default.
• W3136165535 countsByYear W31361655352022 @default.
• W3136165535 crossrefType "journal-article" @default.
• W3136165535 hasAuthorship W3136165535A5003649889 @default.
• W3136165535 hasAuthorship W3136165535A5006829574 @default.
• W3136165535 hasAuthorship W3136165535A5028097742 @default.
• W3136165535 hasAuthorship W3136165535A5036487477 @default.
• W3136165535 hasAuthorship W3136165535A5041492237 @default.
• W3136165535 hasAuthorship W3136165535A5042973046 @default.
• W3136165535 hasAuthorship W3136165535A5053399096 @default.
• W3136165535 hasAuthorship W3136165535A5069537747 @default.
• W3136165535 hasAuthorship W3136165535A5081143070 @default.
• W3136165535 hasBestOaLocation W31361655352 @default.
• W3136165535 hasConcept C121608353 @default.
• W3136165535 hasConcept C126322002 @default.
• W3136165535 hasConcept C141071460 @default.
• W3136165535 hasConcept C143998085 @default.
• W3136165535 hasConcept C159110408 @default.
• W3136165535 hasConcept C168563851 @default.
• W3136165535 hasConcept C2775965419 @default.
• W3136165535 hasConcept C2776256026 @default.
• W3136165535 hasConcept C2776694085 @default.
• W3136165535 hasConcept C2779951463 @default.
• W3136165535 hasConcept C2992435398 @default.
• W3136165535 hasConcept C535046627 @default.
• W3136165535 hasConcept C71924100 @default.
• W3136165535 hasConceptScore W3136165535C121608353 @default.
• W3136165535 hasConceptScore W3136165535C126322002 @default.
• W3136165535 hasConceptScore W3136165535C141071460 @default.
• W3136165535 hasConceptScore W3136165535C143998085 @default.
• W3136165535 hasConceptScore W3136165535C159110408 @default.
• W3136165535 hasConceptScore W3136165535C168563851 @default.
• W3136165535 hasConceptScore W3136165535C2775965419 @default.
• W3136165535 hasConceptScore W3136165535C2776256026 @default.
• W3136165535 hasConceptScore W3136165535C2776694085 @default.
• W3136165535 hasConceptScore W3136165535C2779951463 @default.
• W3136165535 hasConceptScore W3136165535C2992435398 @default.
• W3136165535 hasConceptScore W3136165535C535046627 @default.

• next